MedTrace Logo

Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker

NCT01198808 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2012-01-18

No results posted yet for this study

Summary

Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy.

It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.

Conditions

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Thomas Horn, MD · Department of Urology, Technische Universität München

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01198808 on ClinicalTrials.gov